Azithromycin in the Treatment of M. Avium Complex Lung Disease (NCT00599079) | Clinical Trial Compass
CompletedPhase 4
Azithromycin in the Treatment of M. Avium Complex Lung Disease
United States66 participantsStarted 1993-02
Plain-language summary
To determine the safety and efficacy of azithromycin in the treatment of lung infection with M.avium complex and M. abscessus lung disease.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Meet American Thoracic Society criteria for nontuberculous lung disease: two or more AFB smear positive, culture positive sputums or bronchoscopic samples and/or two or more AFB smear negative respiratory samples with moderate to heavy growth (2+-4+); abnormal CXR consistent with M. avium lung disease; abnormal CXR consistent with M. avium lung disease; absence of other lung pathogens (except for the coexistence of M. abscessus).
* Age 18 and older
* Pretreatment isolate of M. avium complex available for MIC determination
Exclusion Criteria:
* History of macrolide allergy
* Received macrolide therapy in last two months
* Children less than 18 years of age
* If a menstruating female, not pregnant and on adequate birth control
What they're measuring
1
Clinical and microbiological outcomes such as clinical symptoms and laboratory cultures
Timeframe: 6 months
Trial details
NCT IDNCT00599079
SponsorThe University of Texas Health Science Center at Tyler